Compare Inovio Pharmaceuticals Inc (INO) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Motorola Solutions Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Motorola Solutions Inc trades at $443.56 (market cap $74.00B). The key difference: Motorola Solutions Inc is far larger — about 659.6× Inovio Pharmaceuticals Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Motorola Solutions Inc for 100 Days on average.
| INO | MSI | |
|---|---|---|
Market Cap | $112.19M | $74.00B |
Volume | 3,201,278 | 722,147 |
Sector | Health | Technology |
52-Week High | $2.65 | $491.24 |
52-Week Low | $0.66 | $363.83 |
Typical Hold Time | 43 Days | 100 Days |
Enterprise Value | $83.51M | $82.90B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Motorola Solutions (MSI) trades at $443.80, down 1.04% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and net income of $2.15B, supported by a record $15.6B backlog as of Q2 2026 (Zacks Investment Research, 2026-09-28). Recent acquisitions like D-Fend Solutions for $1.5B expand its security portfolio, while a new $2B share repurchase authorization signals confidence (Business Wire, 2026-09-09).
The outlook is positive with a consensus price target of $525.86, implying 18.5% upside, and 71% of analysts rate it a Buy. Risks include elevated debt levels with a debt-to-asset ratio of 47.29% in 2025 and negative net cash flow trends, but strong public safety contract wins and AI integration in video analytics provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
